We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Real-Time Assay Evaluated for Two Sexually Transmitted Diseases

By LabMedica International staff writers
Posted on 21 Apr 2020
Chlamydia trachomatis and Neisseria gonorrhoeae are the two most commonly reported sexually transmitted infections (STIs) in the USA and the numbers of cases are increasing. More...
C. trachomatis and N. gonorrhoeae infections in the rectum and pharynx are important extragenital reservoirs of infection.

Due to their high sensitivity and specificity, nucleic acid amplification tests (NAATs) have become the recommended method for detecting N. gonorrhoeae and C. trachomatis infections of the urogenital tract. The Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) recommends screening of all sexually-active men who have sex with men (MSM) for rectal C. trachomatis and N. gonorrhoeae infections and pharyngeal N. gonorrhoeae, at least annually.

Scientists from the David Geffen School of Medicine (Los Angeles, CA, USA) examined the analytical performance of the Abbott RealTime CT/NG assay (Abbott Laboratories, Abbott Park, IL, USA), including the limit of detection, inclusivity, and analytical specificity for C. trachomatis and N. gonorrhoeae in rectal and pharyngeal specimens. All tests were performed on the Abbott m2000 RealTime system. Elementary Bodies (EB)/mL for C. trachomatis and colony-forming units (CFU)/mL for N. gonorrhoeae, in clinical rectal and pharyngeal swab matrices were measured. Inclusivity was performed against 12 serovars of C. trachomatis and seven strains of N. gonorrhoeae. The analytical specificity was performed using 28 different bacteria and viruses.

The limit of detection for C. trachomatis was 2.56 EB/mL in pharyngeal specimens and 12.8 EB/mL in rectal specimens. The limit of detection for N. gonorrhoeae was 0.0256 CFU/mL for both pharyngeal and rectal specimens. The inclusivity and analytical specificity were 100% for both rectal and pharyngeal specimens. In total, there were 80 specimens tested by the second laboratory. All 40 rectal and pharyngeal specimens spiked with C. trachomatis and all 40 rectal and pharyngeal specimens spiked with N. gonorrhoeae tested positive. C. trachomatis was detected in 0/20 of the N. gonorrhoeae-spiked samples from each anatomic site and N. gonorrhoeae was detected in 0/20 C. trachomatis-spiked samples from each anatomic site.

The authors concluded that their analytical performance data demonstrate that the Abbott CT/NG RealTime assay is an accurate, sensitive, and specific assay in rectal and pharyngeal specimens, supporting the potential of the assay for detection of rectal and pharyngeal C. trachomatis and N. gonorrhoeae infections. The study was published on April 2, 2020 in The Journal of Molecular Diagnostics.





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.